Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options

摘要

Background: Patients with advanced urothelial carcinoma (UC) have poor outcomes, with 5-year survival rates of <5% for those with metastatic, stage IV disease. We have reviewed current treatment paradigms and emerging treatment options for these patients.